Comparison · NCT01006538-sae
Arm A: Epimacular Brachytherapy + Lucentis® vs Arm B (Control): Lucentis ® Only: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm A: Epimacular Brachytherapy + Lucentis® vs Arm B (Control): Lucentis ® Only: serious adverse events. Trial comparisons, record NCT01006538-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01006538-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0287 | 0.014 | 0.058 | wilson | |
| Risk in group 2 | 0 | 0 | 0.0313 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0287 | -0.00588 | 0.058 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to harm, for one more participant with a serious adverse event on Arm A: Epimacular Brachytherapy + Lucentis® than on Arm B (Control): Lucentis ® Only | 34.9 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm A: Epimacular Brachytherapy + Lucentis® | Arm A: A single surgical procedure with epimacular brachytherapy using the VIDION® System, with Lucentis® (0.5 mg) administered on a monthly basis as required.~Epimacular Brachytherapy: Strontium-90. The device delivers 24 Gray of beta radiation to the CNV lesion. Each device is calibrated for a set duration.~Ranibizumab: intravitreal injection of Ranibizumab (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria | 7 | 244 | EG000 |
| Group 2 | Arm B (Control): Lucentis ® Only | Arm B: Lucentis® (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria below.~Ranibizumab: intravitreal injection of Ranibizumab (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria | 0 | 119 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Adverse events (AEs) and serious adverse events (SAEs) are reported between baseline and month 12.
Source ClinicalTrials.gov
Trial
- Title
- Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)
- NCT number
- NCT01006538
- Phases
- PHASE4
- Conditions
- Macular Degeneration
- Interventions
- Epimacular Brachytherapy, Ranibizumab
- Lead sponsor
- King's College Hospital NHS Trust
- Results first posted
- 2019-07-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01006538?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01006538-sae